SCHEMBL6843099

SCHEMBL6843099

FC(F)(F)c1cccc(C=NNC(=S)NC2CC3C=CC2C3)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GALR3 O60755 1/20 0.62
MAPT P10636 6/20 0.58
ALDH1A1 P00352 6/20 0.58
KDM4E B2RXH2 5/20 0.58
KMT2A Q03164 4/20 0.58
L3MBTL1 Q9Y468 2/20 0.58
LMNA P02545 2/20 0.58
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
NPSR1 Q6W5P4 2/20 0.57
MAPK1 P28482 1/20 0.56
TDP1 Q9NUW8 2/20 0.52
POLB P06746 1/20 0.52
RECQL P46063 1/20 0.47
XBP1 P17861 1/20 0.45
MEN1 O00255 2/20 0.44
HTT P42858 1/20 0.44
GAA P10253 2/20 0.43
STS P08842 4/20 0.43
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6843098 1.00 GALR3 (0.62) GALR3MAPTALDH1A1KDM4EKMT2A
SCHEMBL5182488 0.87 MAPK1 (0.66) GALR3MAPTALDH1A1KDM4EKMT2A
SCHEMBL6849487 0.87 MAPK1 (0.66) GALR3MAPTALDH1A1KDM4EKMT2A
SCHEMBL5179735 0.83 ALDH1A1 (0.72) MAPTALDH1A1KDM4EKMT2AL3MBTL1
SCHEMBL5181732 0.83 ALDH1A1 (0.72) MAPTALDH1A1KDM4EKMT2AL3MBTL1
SCHEMBL5180502 0.80 MAPT (0.56) MAPTALDH1A1KDM4EKMT2AL3MBTL1
SCHEMBL6843014 0.80 MAPT (0.56) MAPTALDH1A1KDM4EKMT2AL3MBTL1
SCHEMBL7096679 0.79 MAPT (0.72) MAPTALDH1A1KDM4EKMT2AL3MBTL1
SCHEMBL7096677 0.79 MAPT (0.72) MAPTALDH1A1KDM4EKMT2AL3MBTL1
SCHEMBL5180221 0.78 MAPK1 (0.71) MAPTALDH1A1KDM4EKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6794400-B2 USE AS ANTICANCER AGENTS AND IN OTHER CONDITIONS INVOLVING ABNORMAL CELL PROLIFERATION SUCH AS RHEUMATOID ARTHRITIS CYTOVIA, INC. 2004-09-21 US disclosed
US-20030045581-A1 4-substituted-1- (arylmethylidene) thiosemicarbazide, 4-substituted-1- (arylcarbonyl) thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof DISCOVER GROWTH FUND, LLC (VI) 2003-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045581-A1 4-substituted-1- (arylmethylidene) thiosemicarbazide, 4-substituted-1- (arylcarbonyl) thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP1, CASP3, CASP4 GALR3 3060/4885MAPT 4822/4885ALDH1A1 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.